Literature DB >> 12052034

Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance.

T Sugiura1, Y Kobayashi, S Oka, K Waku.   

Abstract

N -arachidonoylethanolamine (anandamide) was the first endogenous cannabinoid receptor ligand to be discovered. Dual synthetic pathways for anandamide have been proposed. One is the formation from free arachidonic acid and ethanolamine, and the other is the formation from N -arachidonoyl phosphatidylethanolamine (PE) through the action of a phosphodiesterase. These pathways, however, do not appear to be able to generate a large amount of anandamide, at least under physiological conditions. The generation of anandamide from free arachidonic acid and ethanolamine is catalyzed by a degrading enzyme anandamide amidohydrolase/fatty acid amide hydrolase operating in reverse and requires large amounts of substrates. As for the second pathway, arachidonic acids esterified at the 1-position of glycerophospholipids, which are mostly esterified at the 2-position, are utilized for the formation of N -arachidonoyl PE, a stored precursor form of anandamide. In fact, the actual levels of anandamide in various tissues are generally low except in a few cases. 2-Arachidonoylglycerol (2-AG) was the second endogenous cannabinoid receptor ligand to be discovered. 2-AG is a degradation product of arachidonic acid-containing glycerophospholipids such as inositol phospholipids. Several investigators have demonstrated that 2-AG is produced in a variety of tissues and cells upon stimulation. 2-AG acts as a full agonist at the cannabinoid receptors (CB1 and CB2). Evidence is gradually accumulating and indicates that 2-AG is the most efficacious endogenous natural ligand for the cannabinoid receptors. In this review, we summarize the tissue levels, biosynthesis, degradation and possible physiological significance of two endogenous cannabimimetic molecules, anandamide and 2-AG. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052034     DOI: 10.1054/plef.2001.0356

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  86 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 2.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

3.  Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol.

Authors:  Bela Szabo; Michal J Urbanski; Tiziana Bisogno; Vincenzo Di Marzo; Aitziber Mendiguren; Wolfram U Baer; Ilka Freiman
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

4.  Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation.

Authors:  Nina Wettschureck; Mario van der Stelt; Hiroshi Tsubokawa; Heinz Krestel; Alexandra Moers; Stefania Petrosino; Günther Schütz; Vincenzo Di Marzo; Stefan Offermanns
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

Review 5.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

6.  N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.

Authors:  Kazuhito Tsuboi; Christine Hilligsmann; Séverine Vandevoorde; Didier M Lambert; Natsuo Ueda
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

Review 7.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Endocannabinoids selectively enhance sweet taste.

Authors:  Ryusuke Yoshida; Tadahiro Ohkuri; Masafumi Jyotaki; Toshiaki Yasuo; Nao Horio; Keiko Yasumatsu; Keisuke Sanematsu; Noriatsu Shigemura; Tsuneyuki Yamamoto; Robert F Margolskee; Yuzo Ninomiya
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Conformationally constrained analogues of 2-arachidonoylglycerol.

Authors:  Subramanian K Vadivel; Sundararaman Vardarajan; Richard I Duclos; JodiAnne T Wood; Jianxin Guo; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2007-08-21       Impact factor: 2.823

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.